LifeMap Sciences, Inc. Announces Addition to Board of Directors and Provides
Update on Product Portfolio Development
ALAMEDA, Calif., Oct 19, 2012 (BUSINESS WIRE) -- BioTime, Inc. (nyse mkt:BTX) and
its subsidiary, LifeMap Sciences, Inc., today announced the appointment of Louis
E. Silverman to LifeMap Sciences' board of directors.
Mr. Silverman is an experienced health care executive with board level and
operating experience in health care IT, pharmaceuticals, home health care,
worker's compensation managed care and revenue cycle management. From September
2009 through to its successful sale in June of 2012, Mr. Silverman was the Chief
Executive Officer of privately held Marina Medical Billing Service Inc., a
company focused on providing revenue cycle management services nationally to
emergency room physicians. Prior to joining Marina Medical, Mr. Silverman was
President and Chief Executive Officer of Lifecomm, Inc., a Qualcomm Incorporated
incubated wireless health services start-up. From 2000 - 2008, Mr. Silverman was
President and Chief Executive Officer of Quality Systems, Inc., a developer of
medical and dental practice management software, which he led to significant
revenue growth and an increase in market value from $42 million to $1.2 billion.
Previously, Mr. Silverman was the Chief Operations Officer of Corvel Corporation.
Mr. Silverman currently serves as a member of the Board of Directors of Questcor
Pharmaceuticals, Inc., a publicly traded biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Mr. Silverman also serves on the Board of Directors of
Comarco, Inc., a public company. Mr. Silverman earned a Bachelor of Arts degree
from Amherst College and a Masters in Business Administration from Harvard
Graduate School of Business Administration.
In addition, today LifeMap Sciences also announced progress on key development
initiatives. During the final quarter of the calendar year 2012, the company
expects to launch or upgrade its four database products: GeneCards(R), MalaCards,
PanDaTox, and LifeMap Discovery(TM). In addition, LifeMap Sciences will launch
the marketing and sales of BioTime's proprietary research product lines,
including PureStem(TM) human progenitor and human embryonic stem cell lines via
the company's LifeMap BioReagents(TM) portal. Another major LifeMap Sciences
initiative is its therapeutic discovery collaboration with BioTime, which
utilizes the LifeMap Discovery(TM) platform and leverages the LifeMap Sciences
scientific team (including ten Ph.D. and four M.S. biologists and bioinformatics
specialists) to research and identify those progenitor cell lines that are most
likely to be useful in developing cell-based regenerative medicine therapies for
a wide range of diseases. Once identified, selected cell lines will be marketed
by LifeMap Sciences for research purposes via the LifeMap BioReagents(TM) portal
and may be advanced into therapeutic development by BioTime and/or LifeMap
Sciences.
"Adding an experienced health care executive to our Board of Directors and
delivering meaningful enhancements to our product portfolio marks 2012 as a year
of great progress for our company and sets the stage for continued growth and
expansion into 2013," stated David Warshawsky, Ph.D., LifeMap Sciences' Chief
Executive Officer.
About LifeMap Sciences, Inc. |
